A Preliminary Study of <scp>d</scp>-Cycloserine Treatment in Alzheimer's Disease

Tsai, Guochuan E.; Falk, William E.; Gunther, Jeanette

doi:10.1176/jnp.10.2.224

Cited by 35 publications

(32 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, studies were recently conducted to explore if the administration of CYC could improve cognitive functions in humans. Indeed, in some studies, it has been shown to improve cognitive functions in Alzheimer and schizophrenic patients, if administered in a proper dosage (Goff et al, 1995(Goff et al, , 1999Tsai et al, 1998Tsai et al, , 1999, although the results achieved so far are mixed (Laake and Oeksengaard, 2002). Whether the improvement of cognitive functions is caused by an enhancement of NMDA receptor efficacy has so far not been tested in humans.…”

Section: Introductionmentioning

confidence: 99%

Consolidation of Human Motor Cortical Neuroplasticity by D-Cycloserine

Nitsche

Jaussi

Liebetanz

et al. 2004

Neuropsychopharmacol

340

176

View full text Add to dashboard Cite

D-Cycloserine (CYC), a partial N-methyl-D-aspartate (NMDA) agonist, has been shown to improve cognitive functions in humans. However, the neurophysiological basis of this effect is unclear so far. We studied the impact of this drug on long-lasting after-effects of transcranial direct current (tDCS)-generated motor cortical excitability shifts, as revealed by transcranial magnetic stimulation-elicited motor-evoked potentials. While anodal tDCS enhances motor cortical excitability, cathodal tDCS diminishes it. Both effects seem to be NMDA receptor dependent. D-CYC selectively potentiated the duration of motor cortical excitability enhancements induced by anodal tDCS. D-CYC alone did not modulate excitability. The potency of this drug to consolidate neuronal excitability enhancements, most probably by stabilizing the strengthening of NMDA receptors, which is a probable neurophysiological derivate of learning processes, makes it an interesting substance to improve cognitive functions.

show abstract

Section: Introductionmentioning

confidence: 99%

Consolidation of Human Motor Cortical Neuroplasticity by D-Cycloserine

Nitsche

Jaussi

Liebetanz

et al. 2004

Neuropsychopharmacol

340

176

View full text Add to dashboard Cite

show abstract

“…It is classified as a second line drug for the treatment of tuberculosis. It is able to penetrate the central nervous system (CNS) thus its use in Alzheimer's disease and schizophrenia (Goff, Henderson, Evins, & Amico, 1999;Goff, Tsai, Manoach, & Coyle, 1995;Tsai, Falk, & Gunther, 1998;Tsai, Falk, Gunther, & Coyle, 1999) while the effect it has on anxiety disorders remains unclear (Ori et al, 2015;Schade & Paulus, 2016). D-Cycloserine inhibits cell wall synthesis in Gram positive bacteria and M.tuberculosis by inhibition of the incorporation of D-alanine into peptidoglycan pentapeptide (Lambert & Neuhaus, 1972;Vyshepan, Ivanova, & Ledneva, 1962;Wargel, Shadur, & Neuhaus, 1971).…”

Section: D-cycloserine (D-4-amino-3-isoxazolidone) Has Better Activitmentioning

confidence: 99%

A review on comparative mechanistic studies of antimicrobial peptides against archaea

Varnava

Ronimus

Sarojini

2017

Biotech & Bioengineering

View full text Add to dashboard Cite

Archaea was until recently considered as a third domain of life in addition to bacteria and eukarya but recent studies support the existence of only two superphyla (bacteria and archaea). The fundamental differences between archaeal, bacterial, and eukaryal cells are probably the main reasons for the comparatively lower susceptibility of archaeal strains to current antimicrobial agents. The possible emerging pathogenicity of archaea and the role of archaeal methanogens in methane emissions, a potent greenhouse gas, has led many researchers to examine the sensitivity patterns of archaea and make attempts to find agents that have significant anti-archaeal activity. Even though antimicrobial peptides (AMPs) are well known with several published reviews concerning their mode of action against bacteria and eukarya, to our knowledge, to date no reviews are available that focus on the action of these peptides against archaea. Herein, we present a review on all the peptides that have been tested against archaea. In addition, in an attempt to shed more light on possible future work that needs to be performed we have included a brief overview of the chemical characteristics, spectrum of activity, and the known mechanism of action of each of these peptides against bacteria and/or fungi. We also discuss the nature of and key physiological differences between Archaea, Bacteria, and Eukarya that are relevant to the development of anti-archaeal peptides. Despite our relatively limited knowledge about archaea, available data suggest that AMPs have an even broader spectrum of activity than currently recognized.

show abstract

“…Supporting neurotrophic/cognitive effects, DCS can improve cognitive functions in animal studies [171,172] and is used clinically in conjunction with CBT interventions [127]. However, cognition-enhancing effects of DCS in AD have not been conclusively demonstrated [173][174][175].…”

Section: Cognitive Impairment and Dementiamentioning

confidence: 99%

D-Serine in Neuropsychiatric Disorders: New Advances

Durrant

Heresco-Levy

2014

Advances in Psychiatry

View full text Add to dashboard Cite

D-Serine (DSR) is an endogenous amino acid involved in glia-synapse interactions that has unique neurotransmitter characteristics. DSR acts as obligatory coagonist at the glycine site associated with the N-methyl-D-aspartate subtype of glutamate receptors (NMDAR) and has a cardinal modulatory role in major NMDAR-dependent processes including NMDAR-mediated neurotransmission, neurotoxicity, synaptic plasticity, and cell migration. Since either over-or underfunction of NMDARs may be involved in the pathophysiology of neuropsychiatric disorders; the pharmacological manipulation of DSR signaling represents a major drug development target. A first generation of proof-of-concept animal and clinical studies suggest beneficial DSR effects in treatmentrefractory schizophrenia, movement, depression, and anxiety disorders and for the improvement of cognitive performance. A related developing pharmacological strategy is the indirect modification of DSR synaptic levels by use of compounds that alter the function of main enzymes responsible for DSR production and degradation. Accumulating data indicate that, during the next decade, we will witness important advances in the understanding of DSR role that will further contribute to elucidating the causes of neuropsychiatric disorders and will be instrumental in the development of innovative treatments.

show abstract

A Preliminary Study of d-Cycloserine Treatment in Alzheimer's Disease

Cited by 35 publications

References 15 publications

Consolidation of Human Motor Cortical Neuroplasticity by D-Cycloserine

Consolidation of Human Motor Cortical Neuroplasticity by D-Cycloserine

A review on comparative mechanistic studies of antimicrobial peptides against archaea

D-Serine in Neuropsychiatric Disorders: New Advances

Contact Info

Product

Resources

About